Objective: Sleep disturbance is common in dementia, although it is unclear whether differences in sleep architecture precede dementia onset. We examined the associations between sleep architecture and the prospective risk of incident dementia in the community-based Framingham Heart Study (FHS).
Disturbed sleep is a common feature of dementia, including dementia due to Alzheimer disease (AD). 1 Cross-sectional studies demonstrate that aspects of sleep architecture differ in patients with dementia as compared to controls. 2, 3 Different stages of sleep may differentially affect key prodromal features of AD pathophysiology, including the generation 4 and clearance of b-amyloid (Ab), 4 which aggregates into oligomers and plaques in AD. 5 Sleep is associated with a marked increase in the clearance of extracellular Ab, likely reflecting increased glymphatic flow. 6 However, the temporal sequence between alterations in sleep architecture and dementia onset remains unclear. Clarifying the role of sleep in the onset of dementia may have important clinical applications, from the development of biomarkers to generating potential avenues for intervention. Accordingly, we examined whether aspects of sleep architecture were associated with the incidence of all-cause dementia and AD dementia in the community-based Framingham Heart Study over a maximum of 19 years of follow-up.
METHODS This study involved the Framingham Heart Study
Offspring cohort, 7 which commenced in 1971. Participants have been studied across 9 examination cycles approximately every 4 years, with the latest cycle concluding in 2014. During the sixth examination cycle (1995) (1996) (1997) (1998) , 699 Offspring cohort participants and 298 Omni 1 cohort participants (aged $40 years, 50% male) completed an overnight polysomnography (PSG) as part of the multicenter Sleep Heart Health Study. 8 The present study reports on the Offspring study participants only for whom we have data for incident dementia. Of the 699 Offspring participants with PSG, we excluded 370 participants aged younger than 60 years at the time of the PSG, 2 with prevalent dementia, 5 who were without follow-up for dementia, and 1 who was missing PSG data. Thus, our final sample comprised 321 participants.
Standard protocol approvals, registrations, and patient consents. All participants provided written informed consent.
The study was approved by the institutional review board of Boston University Medical Center.
Assessment of PSG. Participants completed home-based PSG.
The methods, including scoring guidelines and reliability, have been published previously. [8] [9] [10] Briefly, sleep stages were scored in 30-second epochs by the criteria outlined by Rechtschaffen and Kales. 11 Exposures for the present study included the percentage of time in stage 1, stage 2, slow-wave sleep (SWS; stages 3 and 4 combined), and REM sleep. Measures of sleep continuity, fragmentation, and sleep-disordered breathing were examined as additional exposures. These exposures included total sleep time, sleep onset latency, REM sleep latency, sleep efficiency (percentage of total sleep time/total time in bed), wake after sleep onset, and the apnea-hypopnea index (AHI) accompanied by a 4% or greater oxygen desaturation.
Ascertainment of incident dementia. The Framingham Heart
Study (FHS) monitors incident dementia through continuous surveillance of the cohort. 12 Cognitive screening is performed at each FHS examination cycle using the Mini-Mental State Examination (MMSE) 13 supplemented with extensive neuropsychological testing at selected examination cycles. Participants are flagged with suspected cognitive impairment using the MMSE if (1) performance falls below education-based cutoff scores, 14 (2) a decline of 3 or more points is observed between consecutive examinations, or (3) a decrease of 5 or more points is observed from the participant's highest past MMSE score. Participants are also flagged following referrals or concern expressed by the participant, their family, or primary care physician. Once flagged with suspected cognitive impairment, participants complete annual neuropsychological and neurologic evaluations until they develop dementia or are adjudicated to be normal. Evaluations indicative of possible dementia are followed by referral to our study dementia review committee, comprising a neurologist and neuropsychologist. The committee adjudicates a diagnosis of dementia in line with the DSM-IV. 15 A diagnosis of AD dementia is based on the criteria of the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association for definite, probable, or possible AD. 16 Statistical analysis. After confirming the proportionality of hazards assumption, we used SAS software V9.4 (SAS Institute, Cary, NC) to estimate Cox proportional hazards regression models. The sleep exposures at baseline were related prospectively to the incidence of dementia. Surveillance for dementia commenced from examination cycle 6 (baseline) to the time of incident event over a maximum of 19 years. Non-events were censored at death or until the last date they were known to be dementia-free, also up to 19 years. Hazard ratios (HR) are presented accompanied by 95% confidence intervals (CIs). A square root transformation was applied to SWS. Log transformations were applied to sleep latency, wake after sleep onset, and the AHI to restore normality. All other sleep variables were left as continuous and untransformed variables except sleep efficiency and REM sleep latency, which could not be normalized through transformation. These variables were analyzed according to tertiles, using the highest tertile as the reference group.
Analyses were performed according to 2 statistical models. Model 1 included adjustments for age and sex. Model 2 included additional adjustments for body mass index, education (dichotomized at the level of college degree attainment), positivity for an APOE e4 allele, systolic blood pressure, current smoking, prevalent diabetes, prevalent heart disease, depressive symptoms (Center for Epidemiologic Study Depression scores $16), use of antidepressants (monoamine oxidase inhibitors [MAOIs] , nontricyclic antidepressants other than MAOIs, and tricyclic antidepressants), anxiolytics (benzodiazepines), antihypertensive medications, and medications to aid sleeping (participant self-reporting use of pills or medications at least once a month to help them sleep). Persons with missing data were excluded from analysis.
Sensitivity analysis. We examined the associations between absolute time in each sleep stage (rather than percentage of time) and the risks of incident all-cause and AD dementia. We also examined for interactions between APOE e4 allele status and each sleep stage. We then explored for factors that may explain the observed association between REM sleep percentage and dementia risk. We examined the associations between REM sleep percentage and incident all-cause and AD dementia after excluding (1) persons with mild cognitive impairment (MCI) at baseline, (2) the first 3 years of follow-up (thereby excluding early converters to dementia), (3, 4) persons with a very early or late chronotype (bottom 5% and top 5% of mid-sleep time [,1 AM and .4 AM, respectively]), (5) persons with a high number of arousals from REM sleep (top 10% [.30 .64 arousals/h]), (6) persons with a high number of arousals from REM sleep due to hypopnea irrespective of desaturation (top 10% [.14.77 arousals/h]), and (7) persons with a high number of arousals from REM sleep due to obstructive apnea irrespective of desaturation (top 10% [.10.00 arousals/h]). Sensitivity analyses were adjusted for model 1 covariates. Results were considered significant if p , 0.05, except tests of interaction, which were considered significant if p , 0.10.
RESULTS Sample overview. Sample demographics and sleep measures at baseline are presented in tables 1 and 2, respectively. Over a mean of 12 (SD 5) years of follow-up, we observed 32 cases of incident dementia, 24 of which were due to AD dementia. Of the incident all-cause dementia cases, 25% occurred within the first 6.6 years, and 50% occurred between 6.6 and 11.8 years of follow-up, respectively.
Sleep stages and risk of dementia. Lower REM sleep percentage was associated with an increased risk of all-cause dementia across both statistical models (table 3) . After adjustment for age and sex, each percentage decrease in REM sleep was associated with approximately a 9% increase in the risk of incident dementia. The effect sizes were similar for AD dementia. Stages 1, 2, and SWS were not significantly associated with dementia risk. Although higher total sleep time was associated with a lower risk of all-cause dementia (HR 0.994; 95% CI 0.989-0.999) and AD dementia (HR 0.993; 95% CI 0.987-0.999) in model 1, the effect sizes were small. Sleep onset latency, sleep efficiency, and the AHI were not related to dementia incidence in our sample (table e-1 at Neurology.org).
Sensitivity analysis. Results for absolute time in each sleep stage were consistent with our primary models, although effect sizes for time in REM sleep and dementia were less marked (table e-2). If we consider only those persons who developed new-onset dementia during follow-up, persons who spent a greater proportion of their time in REM sleep took longer to develop dementia (r 5 0.37, p 5 0.04). A (14) 49 (14) 46 (13) Diabetes mellitus, n (%) 46 (14) 36 (13) 10 (31) Prevalent CHD, n (%) 28 (9) 25 (9) 3 (9) Current smoker, n (%) 32 (10) 30 (10) 2 (6) APOE e41, n (%) 71 (22) 60 (21) 11 (34) CES-D scores ‡16, n (%) 24 (8) 20 (7) 4 (13) Antidepressant use, n (%) 11 (3) 9 (3) 2 (6)
Benzodiazepine use, n (%) 12 (4) 12 (4) DISCUSSION This prospective study of a population-based sample reveals that shorter REM sleep percentage and longer latency to REM sleep were both independently associated with a higher risk of incident dementia. Greater wake after sleep onset, a measure of difficulty maintaining sleep, was also associated with an increased risk of dementia, but only in our fully adjusted statistical model. Stages of non-REM sleep were not associated with dementia incidence in our sample.
Previous prospective studies have linked objective sleep disturbance to the risk of clinical cognitive impairment. In a substudy of the Study of Osteoporotic Fractures, sleep-disordered breathing (defined as an AHI $15) was associated with the risk of incident clinical cognitive impairment and dementia (as a combined outcome) over a median of 5 years follow-up. 17 In the Rush Memory and Aging Project, 10 consecutive days of actigraphy-assessed sleep fragmentation was associated with an increased risk of AD over a mean of 3 years follow-up. 18 Despite these insights, prospective population-based studies have been of short duration and have not examined the association between sleep stages and the risk of dementia.
Current research on sleep and AD is mostly focused on SWS. 4, 19, 20 However, our findings implicate less REM sleep, and not SWS, with the risk of dementia. In support of our findings, patients with dementia display less REM sleep on average as compared to controls without dementia.
2,3 A populationbased study using PSG recently demonstrated that time in REM sleep is reduced in those with as compared to without cognitive impairment, perhaps as a result of sleep-disordered breathing. 21 In the Osteoporotic Fractures in Men Study, men with the lowest (vs highest) quartile of REM sleep percentage experienced more than twice the annual rate of decline in modified MMSE scores. 22 REM sleep latency is also longer in patients with AD dementia as compared to controls with latency appearing to increase across categories of AD severity. 3 In the same study, REM sleep percentage was positively correlated with CSF levels of Ab1-42 in 48 patients with AD. Our results add to these studies by demonstrating that less REM sleep is associated prospectively with an increased risk of incident dementia among community-dwelling individuals. The observed effect size was large, with each percentage reduction in REM sleep associated with an approximate 9% increase in dementia risk. Overall, our findings suggest that future research should consider the role of REM sleep in the pathophysiology of dementia.
The mechanisms linking REM sleep to incident dementia are yet to be determined. In our study, the association between REM sleep percentage and dementia was independent of numerous confounders such as pharmacologic intervention for mood disorders, which adversely interfere with REM sleep. 23 REM sleep behavior disorder has been associated with dementia and is clinically diagnostic of dementia due to the synucleinopathies. 24 Cases of dementia due to the synucleinopathies did not drive our results given that effect sizes were similar when examining incident all-cause dementia (which included 6 cases of dementia with Lewy bodies) and AD dementia (no cases of mixed AD with Lewy bodies, Parkinson disease, or multiple system atrophy).
Cholinergic neurons are important determinants of REM sleep, 25, 26 with cholinergic activity low during SWS and high during REM sleep. 27 AD is well-known to be associated with loss of cholinergic function, from the degeneration of cholinergic projections in the basal forebrain and changes in acetylcholine release, high-affinity choline uptake, and acetylcholine receptor expression. 28, 29 Thus, loss of cholinergic function may underpin the association between reduced REM sleep and dementia risk, i.e., a healthy cholinergic system maintains REM sleep metrics better than a slowly degenerating cholinergic system. However, in our study, the association between REM sleep percentage and incident dementia was not driven by persons with MCI at the time of polysomnography or those who converted to dementia within the first 3 years of follow-up. Such findings suggest that the association between REM sleep and dementia was not simply the result of neurologic changes that occurred in the late prodromal phase of dementia.
The association between REM sleep percentage and dementia was not driven by persons with early or late chronotypes. However, without information on shift work, we were unable to ascertain whether a late or early chronotype resulted in sleep outside of a physiologically preferred sleep period. The absence of this information prevented us from determining circadian rhythm sleep disorders. The effect between REM sleep percentage and dementia was attenuated after excluding persons with a high number of arousals from REM sleep due to hypopneas, suggesting a possible contributing role of sleep-disordered breathing. However, even after excluding persons with a high number of arousals from REM sleep, each percentage reduction in REM sleep percentage was associated a nonstatistically significant 6% increase in all-cause dementia risk, suggesting contributions from other unmeasured factors.
It is possible that reduced REM sleep may be a marker of increased responsiveness to stress, 30 with heightened anxiety also implicated as a risk factor for dementia. 31 On the other hand, REM sleep is thought to promote synaptic consolidation and to upregulate the activity of immediate early genes implicated in synaptic plasticity. 27, 32 Thus, REM sleep may also buffer against synaptic loss and cognitive decline by assisting in the production of new connections and networks. Though there are biologically plausible mechanisms to explain our results, more studies are needed to explore the mechanisms linking REM sleep to AD pathology and incident dementia.
Strengths of the current study include the population-based sample, rigorous surveillance for incident dementia, long duration of follow-up, and use of PSG to measure sleep architecture. Limitations of the current study include the small sample size and a small number of incident events. Consequently, we had limited power to detect weaker but potentially important associations with other sleep-related exposures and dementia. For example, an AHI $15 has been associated with clinical cognitive impairment, 17 yet we did not have the power to examine this threshold in the present study. Second, as our sample was of Caucasian decent, it is unclear how our results generalize to other ethnic groups. Future research should confirm our findings and determine the mechanisms linking REM sleep to incident dementia.
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